Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis

Mult Scler. 2012 Aug;18(8):1185-7. doi: 10.1177/1352458511433920. Epub 2012 Jan 30.

Abstract

Previous infection with Epstein-Barr virus (EBV) and infectious mononucleosis are established multiple sclerosis (MS) risk factors, and elevated serum titers of anti-EBV nuclear antigen (anti-EBNA) antibodies in healthy adults are strongly correlated with future MS risk. In this prospective study, we investigated the association between EBV neutralizing antibodies and MS risk. MS risk tended to be higher in individuals with high titers of neutralizing antibodies compared to those with low titers (relative risk [RR] = 2.2, 95% confidence interval [CI] 0.97-5.1). This association was attenuated after adjustment for anti-EBNA1 IgG Ab titers (RR = 1.4, 95% CI 0.5-3.5). This preliminary finding warrants further study in a larger population.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Neutralizing / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Epstein-Barr Virus Infections / diagnosis
  • Epstein-Barr Virus Infections / epidemiology
  • Epstein-Barr Virus Infections / immunology*
  • Epstein-Barr Virus Nuclear Antigens / immunology
  • Female
  • Herpesvirus 4, Human / immunology*
  • Humans
  • Logistic Models
  • Multiple Sclerosis / epidemiology
  • Multiple Sclerosis / immunology*
  • Odds Ratio
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Up-Regulation
  • Viral Matrix Proteins / immunology

Substances

  • Antibodies, Neutralizing
  • EBV-associated membrane antigen, Epstein-Barr virus
  • Epstein-Barr Virus Nuclear Antigens
  • Viral Matrix Proteins